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Background:High-grade serous ovarian cancer (HGSOC) intratumoral 54 
vasculature evolution remains unknown. The study investigated changes in 55 
tumor microvessel density (MVD) in a large cohort of paired primary and 56 
recurrent HGSOC tissue samples and its impact on patients’ clinico-57 
pathological outcome. 58 
Methods:222 primary (pOC) and recurrent (rOC) intra-patient paired HGSOC 59 
were assessed for immunohistochemical expression of angiogenesis-60 
associated biomarkers (CD31, to evaluate MVD, and VEGF-A). Expression 61 
profiles were compared between pOCs and rOCs and correlated with patients´ 62 
data. 63 
Results:High intratumoral MVD and VEGF-A expression were observed in 64 
75.7%(84/111) and 20.7%(23/111) pOCs, respectively. MVDhigh and VEGF(+) 65 
samples were detected in 51.4%(57/111) and 20.7%(23/111) rOCs, 66 
respectively. MVDhigh/VEGF(+)  co-expression was found in 19.8%(22/111) and 67 
8.1%(9/111) of pOCs and rOCs, respectively(p=0.02). Pairwise analysis 68 
showed no significant change in MVD(p=0.935) and VEGF-A(p=0.121) levels 69 
from pOCs to rOCs. MVDhigh pOCs were associated with higher 70 
CD3(+)(p=0.029) and CD8(+)(p=0.013) intratumoral effector TILs, while VEGF(+)  71 
samples were most frequently encountered among BRCA-mutated tumors 72 
(p=0.019). Multivariate analysis showed VEGF and MVD were not independent 73 
prognostic factors for OS. 74 
Conclusion:HGSOC intratumoral vasculature did not undergo significant 75 
changes during disease progression. High concentration of CD31(+)vessels 76 
seems to promote recruitment of effector TILs. The study also provides 77 
preliminary evidence of the correlation between VEGF-positivity and BRCA 78 
status. 79 
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BACKGROUND 83 
High-grade serous ovarian carcinoma (HGSOC) still accounts for the highest 84 
mortality rate among all ovarian cancer (OC) histotypes, with almost 80% of all 85 
new deaths from OC being caused by this distinct subgroup of ovarian tumors 86 
[1-4]. International groups of opinion leaders have recognized the designing of 87 
new translational studies on recurrent and end-stage HGS tumor tissue 88 
samples as a key “unmet need” in the understanding of HGSOC biology and 89 
clonal evolution [4].  90 
In this scenario, analysis of the evolution process affecting intratumoral 91 
vasculature during HGSOC progression is a pivotal issue to be still elucidated. 92 
After decades of paralysis in primary OC first-line chemotherapy treatment, 93 
indeed, incorporation of bevacizumab in the upfront regimen for advanced 94 
newly diagnosed disease [5] has changed the “standard of care paradigm” of 95 
advanced primary OC, although characterized by less survival impact than 96 
expected [6,7,8]. Thus, understanding changes in the vasculature or 97 
identification of prognostic biomarkers of response to vasculature targeting is 98 
needed. Unfortunately, there are currently no predictive biomarkers to tailor 99 
bevacizumab treatment in OC patients.   100 
A full knowledge of molecular changes involving intratumoral vasculature from 101 
primary to recurrent HGSOC is still lacking and may provide new opportunities 102 
to: 1) tailor treatment with currently available anti-angiogenetic agents, 2) shed 103 
light on acquired resistance mechanisms, 3) develop new targeted therapies.  104 
Aim of this study was to identify changes occurring from primary to recurrent 105 
HGSOC in tumor tissue expression of the angiogenesis-associated biomarkers 106 
CD31, applied for detecting microvessels density (MVD) [9-11], and VEGF-107 
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A[12], by analyzing a large cohort of paired primary and recurrent HGSOC 108 
tissue samples. Secondary endpoints included the correlation of biomarkers 109 
expression with patients’ clinico-pathological characteristics and survival data. 110 
 111 
MATERIALS AND METHODS 112 
Sample Collection 113 
Paired cancer tissue samples belonging to HGSOC patients were collected 114 
during primary and secondary cytoreduction. Patients were treated with primary 115 
debulking surgery followed by platinum-based chemotherapy between 1985 116 
and 2013 and were retrospectively and consecutively selected from OCTIPS 117 
(Ovarian Cancer Therapy–Innovative Models Prolong Survival, Agreement 118 
No.279113-2) Consortium database. Included patients underwent both primary 119 
(pOC) and recurrent (rOC) surgery in one of the European Gynecologic 120 
Oncology referral Centers of the following Institutions: Charité 121 
Universitätsmedizin Berlin, Germany; Catholic University of Leuven, Belgium; 122 
Imperial College, London, UK; University of Edinburgh, UK; University Medical 123 
Center Hamburg-Eppendorf, Germany. 124 
Inclusion criteria were: availability of paired primary and recurrent cancer tissue 125 
samples from HGSOC patient together with clinical annotation. Exclusion 126 
criterion was: neoadjuvant chemotherapy treatment, due to the need to analyze 127 
primary chemo-naïve tumors. Approval from each local ethics committee was 128 
obtained (EK207/2003, ML2524, 05/Q0406/178, EK130113, 06/S1101/16). All 129 
included samples underwent central histopathological assessment to confirm 130 
HGSOC histology and ensure tumor tissue content and quality. 131 
Immunohistochemistry 132 
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Tissue microarrays (TMA) were constructed for immunohistochemical staining. 133 
Each primary and recurrent tumor tissue sample was represented within the 134 
TMA by two tumor cores, each containing at least 90% of cancer cells.  135 
Sections from TMA were deparaffinized in xylol, rehydrated in graded alcohol 136 
and boiled in pressure cooker for 5 minutes in citrate buffer (pH=6), for CD31 137 
staining, or in EDTA (pH=9), for VEGF staining. Rabbit anti-human CD31 138 
antibody (clone ab32457;Abcam,Cambridge,MA,USA) and rabbit anti-human 139 
VEGF-A antibody (clone A-20;Santa Cruz Biotechnology,Dallas,TX,USA) were 140 
diluted 1:20 and 1:250, respectively, and incubated on slides for 60 minutes at 141 
room temperature. Bound antibodies were visualized using DAKO Real 142 
Detection System and DAB+ (3,3′-diaminobenzidine; DAKO, 143 
Glostrup,Denmark) as a chromogen. Finally, slides were co-stained with 144 
hematoxylin.  145 
CD31 stained samples were assessed in terms of MVD. MVD was determined 146 
by averaging the number of vessels from three distinct areas of tumor with 147 
highest vessels density examined at 200x magnification [13-15]. 148 
Samples were further classified into “MVDhigh” (≥16.3 vessels) or “MVDlow” 149 
(<16.3 vessels), establishing the cut-off level of MVD count for dichotomization 150 
at first quartile (primary samples), being the value able to maximize difference 151 
in OS hazard ratio [Table S1][13,15,16].  152 
For VEGF staining evaluation, the number of stained tumor cells within the 153 
whole TMA cores (0%=0; 1-10%=1; 11-50%=2; >50%=3) was multiplied with 154 
the intensity of staining (negative=0; weak=1; moderate=2; strong=3)[17], 155 
resulting in a semiquantitive immunoreactivity score (IRS) ranging from 0 to 9. 156 
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Samples were classified as “VEGF(+)”, for VEGF-high tumor expression (IRS=4-157 
9), or as “VEGF(-)”, for absent/weak focal staining (IRS=0-3). 158 
As positive control for IHC were used human liver sections. Samples staining 159 
was assessed independently by two co-authors (IR and SDE). 160 
Patients’ clinico-pathological data 161 
Patients’ clinico-pathological data, including somatic BRCA status from 52 162 
included patients, were retrieved from OCTIPS Consortium database [18]. 163 
GCIG criteria were applied to define platinum-resistance and platinum-164 
sensitivity[19]. RECIST Criteria were applied during patients’ follow-up to define 165 
HGSOC relapse. No residual tumor was defined intraoperatively by the surgeon 166 
in case no macroscopic tumor could be detected at the end of cytoreduction. 167 
In order to investigate any association between different tumor vasculature 168 
profiles and intratumoral immune infiltrate in both pOCs and rOCs, MVD and/or 169 
VEGF profiles were matched with previous OCTIPS data on tumor infiltrating 170 
lymphocytes (TILs), assessed through the immunohistochemical expression of 171 
CD3, CD4 and CD8 biomarkers, as previously reported [21]. Furthermore, 172 
immunosuppressive TILs were evaluated through the expression of T 173 
regulatory cells-specific biomarker FoxP3, using the mouse anti-human FOXP3 174 
antibody (clone ab20034; Abcam, Cambridge, MA, USA, 1:200, 1.5 h at room 175 
temperature). The count of stained FoxP3-positive TILs was then performed 176 
automatically with the VM Scope Quantifier, as previously reported [21]. 177 
Statistical Analysis 178 
Statistical analysis was performed using SPSS version 22.0 (SPSS 179 
Inc,Chicago,IL,USA). Difference in biomarker expression between pOCs and 180 
rOCs was assessed through the correlation test (Spearman coefficient, 2-181 
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tailed) and “Wilcoxon signed rank” non-parametric test for related samples. 182 
Fisher’s exact test was applied to correlate MVD and/or VEGF tumor 183 
expression with patients’ clinico-pathological categorical data. Patients’ 184 
progression-free interval (PFI), progression-free survival (PFS) and overall 185 
survival (OS) were identified through Kaplan–Meier analysis (Log-Rank test). 186 
PFI was defined as the time interval from the last adjuvant chemotherapy to 187 
relapse, whereas progression-free survival (PFS) was established as the time 188 
interval between first recurrence diagnosis and tumor progression. Univariate 189 
and multivariate survival analyses were performed applying Cox-regression 190 
model. Multivariable models were obtained among variables reporting a p-value 191 
≤0.1 in univariate analysis. P values ≤0.05 were evaluated statistically 192 
significant. 193 
 194 
 195 
RESULTS 196 
 197 
222 intra-patient paired primary and recurrent HGSOC tissue samples derived 198 
from 111 patients were included. Patients’ characteristics are listed in Table 1. 199 
To note, only 2/111 (1.8%) patients received bevacizumab in front-line 200 
chemotherapy, thus the staining of recurrent samples have not been influenced 201 
by first-line administration of anti-angiogenetic compounds.  202 
 203 
MVD staining 204 
MVDhigh staining was detected in 75.7% (84/111) of pOC and in 51.4% (57/111) 205 
of rOC, whereas MVDlow staining was found in 24.3% (27/111) and in 48.6% 206 
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(54/111) of pOC and rOC, respectively. MVDlow staining was twice as prevalent 207 
in relapsed tumours compared to primary disease (p=0.0003, Fisher’s exact 208 
test, Fig.1a-d). Nevertheless, globally, pair-wise analysis revealed no tendency 209 
towards a change in MVD to higher or lower levels in recurrent samples 210 
(p=0.935, Wilcoxon test; Fig.1e), as well as no significant correlation between 211 
pOCs and rOCs in MVD was reported (Spearman correlation, p=0.920; 212 
Spearman coefficient: 0.01). 213 
 214 
VEGF-A expression 215 
 216 
VEGF IRS distribution in both pOCs and rOCs is shown in Fig.2a,2d. The same 217 
percentage of VEGF(+) (20.7%, 23/111) and VEGF(-) (79.3%, 88/111) tumor 218 
samples was found between pOCs and rOCs, respectively, (p=1, Fisher’s exact 219 
test, Fig.2b,c,e,f), although no significant correlation between pOCs and rOCs 220 
VEGF IRS values could be observed (p=0.505, Spearman coefficient 0.06). 221 
Furthermore, pairwise analysis confirmed no tendency towards a change in 222 
VEGF IRS levels at tumor relapse (p=0.121,Wilcoxon test; Fig.2g). 223 
 224 
MVDhigh and VEGF(+) co-expression in pOCs versus rOCs. 225 
MVDhigh and VEGF(+) co-expression was more frequent in pOCs group (22/111, 226 
19.8%) compared to rOCs (9/111, 8.1%) (p=0.02, Fisher’s exact test, Fig.S1). 227 
 228 
Relationship between MVD and/or VEGF-A expression with TILs. 229 
Results showed that MVDhigh levels in pOCs samples were associated with 230 
higher CD3(+) (p=0.029, Mann-Whitney test) and CD8(+) (p=0.013) effector TILs, 231 
but not with a higher FoxP3(+) (p=0.443) T-regulatory cells infiltrate. To note, 232 
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the correlation between MVD and CD3(+)/CD8(+) TILs disappeared at tumor 233 
recurrence. No significance between pOCs or rOCs VEGF expression or 234 
MVDhigh+VEGF(+) co-staining  with TILs was reported (Fig.S2, Table S2).   235 
 236 
MVD and/or VEGF-A profiles and patients’ clinico-pathological factors. 237 
Analysis on the correlation between MVD and/or VEGF expression in pOCs 238 
with patients’ clinico-pathological characteristics is shown in Table 2. In 239 
particular, VEGF(+) primary HGSOCs and MVDhigh/VEGF(+) primary samples 240 
were most frequently encountered among somatic-BRCA mutated tumors 241 
compared to somatic-BRCA wild type cases (p=0.019, Fisher’s exact test). No 242 
further significant associations between different intratumoral vasculature 243 
profiles and patients’ age at diagnosis, FIGO stage, residual tumor after primary 244 
debulking or first-line platinum response was identified.  245 
Decrease of VEGF expression in rOCs was observed only in BRCA-mutated 246 
patients (p=0.053, Wilcoxon test), although this association did not reach 247 
statistical significance (Fig.S3). 248 
 249 
Survival  250 
Patients, whose pOCs resulted MVDhigh, VEGF(+) or co-stained for both 251 
biomarkers, were found to have a significantly improved OS compared to 252 
patients without these intratumoral profiles at primary disease (Fig.3g-i). In 253 
particular, median OS for MVDhigh and MVDlow patients was 67 and 46 months 254 
respectively (p=0.019), median OS for VEGF(+) and VEGF(-) patients resulted 255 
76 versus 52 months, respectively (p=0.036), while median OS for patients with 256 
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co-stained pOCs was 76 months, compared to 52 months in women without 257 
co-expression (p=0.021). 258 
On the contrary, no influence of pOCs or rOCs MVD and/or VEGF expression 259 
on patients’ time to progression after primary (PFI) or first recurrent disease 260 
(PFS) was reported (Fig.3a-f). 261 
Multivariate analysis for OS and PFI was carried out on the whole patients’ 262 
population (n=111) and also on the subgroup of patients (n=52) with known 263 
tumor somatic-BRCA status. Table 3a,b shows that VEGF-A was not found to 264 
be an independent prognostic factor for OS anymore when considering also 265 
somatic BRCA mutational status. Only somatic BRCA mutation (HR:0.354, CI 266 
95%:0.133-0.994; p=0.038), high CD4(+) TILs (HR:0.997, CI 95%:0.995-1.000; 267 
p=0.038) and first-line platinum response (HR:0.216, CI 95%:0.051-0.991; 268 
p=0.037) were found to independently improve HGSOC patients’ OS. 269 
When analyzing the PFI in patients with or without BRCA somatic mutations, 270 
advanced FIGO stage (HR:18.261, CI 95%:1.28-260.17; p=0.032) and low 271 
CD4(+) TILs (HR:0.996, CI 95%:0.993-0.998; p=0.001) were the only 272 
independent poor prognostic factors (Table 3c,d).  273 
 274 
 275 
DISCUSSION  276 
 277 
In the last decade, “omics” sciences provided fundamental insight into the 278 
understanding of HGSOC biology [3], showing as one distinct malignancy with 279 
its own characteristic phenotype, etiology and progression profile [22]. Although 280 
known for its aggressive behavior, HGSOC has a higher change to show 281 
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durable response after first-line chemotherapy, compared to other OC 282 
histologies [23], as well as its common platinum-sensitivity allows it to access 283 
a more varied panel of experimental second-line combinations [24].  284 
Unfortunately, progression from HGSOC is often rapid and chemo-resistance 285 
develops [4].  286 
In this context, understanding the biological changes occurring to HGSOC 287 
during disease progression is an essential issue through which new identified 288 
biomolecular signatures, marking the HGSOC clinical evolution, could help 289 
developing new tailored treatment strategies.      290 
In this study, OCTIPS Consortium aimed to identify modifications involving 291 
HGSOC intratumoral vasculature from primary to recurrent disease, by 292 
assessing the evolution of cancer MVD and VEGF-A expression. Results 293 
showed that: 1) MVD and/or VEGF levels did not undergo significant changes 294 
from pOC to rOC (being in line with already available clinical findings, as 295 
bevacizumab is showing mild improvement in PFS, in both primary and 296 
relapsed situation)[5,7,8]; 2) High MVD levels in pOC seems to sustain the 297 
intratumoral recruitment of effector TILs and were associated with better OS in 298 
HGSOC patients; 3) VEGF(+) HGSOCs were most frequently encountered 299 
among somatic BRCA-mutated tumors and VEGF-positivity correlates with 300 
better OS in this HGSOC cohort; 4) MVD and VEGF were not independent 301 
prognostic factor for OS when taking into account the BRCA mutational status 302 
and TILs profile. 303 
The definition of “intratumoral microvessel density” has been coined in the 304 
middle of 90’s to objectivize the entity of blood supply available within the tumor 305 
mass to sustain cancer growth[25]. Intratumoral vessels are usually 306 
 12 
characterized by impaired vascular maturation, poor functionality and defects 307 
in endothelial architecture. Immaturity of the new generated tumor-associated 308 
vasculature results in excessive permeability, poor perfusion and imperfect 309 
blood flow[26]. 310 
During the last 20 years, different studies recognized “high” MVD a poor 311 
prognostic factor for cancer patients[27-29], including women affected by 312 
OC[30]. Different biomarkers have been adopted to assess MVD in OC, 313 
including Von Willebrand Factor, CD105, CD34 and CD31, being CD34 the 314 
most used MVD detector and the biomarker associated with the poorest HR for 315 
OS (HR:1.67, C.I.95%:1.36-2.35) compared to other MVD detectors (HR:1.32, 316 
C.I.95%:0.82-1.82)[30]. 317 
CD31, also known as “platelet endothelial cell adhesion molecule-1” (PECAM-318 
1) is a transmembrane glycoprotein expressed on endothelial cells, platelets, 319 
neutrophils and T-cells. It is a key factor to maintain the integrity of endothelial 320 
cells permeability barrier and to promote the controlled activation of T-cells and 321 
their survival[11,31,32], thus being expression of a normalized endothelium 322 
able to sustain the correct trafficking of T-cells into the tumor. In line with CD31 323 
biological role, we observed that MVDhigh levels in pOCs samples correlated 324 
with higher CD3(+) and CD8(+) TILs, but not with a higher FoxP3(+) T-325 
lymphocytes infiltrate, thus suggesting that a high concentration of intratumoral 326 
CD31(+) vessels might be able to promote the intratumoral recruitment of 327 
effector T-cell populations, thus ultimately improving patients’ survival[33]. 328 
Recently, Bais et al.[16] identified CD31-dependent MVD as a predictive 329 
biomarker for bevacizumab response in first-line treated OC patients. This 330 
finding might be consequence of intratumoral endothelial maturity, represented 331 
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by high CD31-dependent MVD levels, able to ensure a normalized blood flow, 332 
which is pivotal for intratumoral drug delivery and efficacy[26]. 333 
Vascular Endothelial Growth Factor (VEGF) is a key angiogenetic cytokine that 334 
regulates cell mitosis and endothelial cells permeability[34]. Overexpression of 335 
VEGF has been found to correlate with cancer relapse and decreased survival 336 
in patients affected by different solid tumors, including OC[35]. Despite previous 337 
studies, absence of significant changes in MVD and VEGF profile following 338 
disease progression of this unique cohort, indicates that these markers are not 339 
major drivers of molecular cancer evolution in vivo, but rather remain supportive 340 
factors. 341 
One of the most intriguing outcomes of our study is that VEGF-A 342 
overexpression in pOC has been most frequently found among patients with a 343 
cancer somatic mutation of BRCA1/2 genes. This finding is in line with two other 344 
previously published papers. In 2013, Danza[36] observed that BRCA-mutated 345 
breast cancer patients reported higher levels of VEGF mRNA (P=0.04) 346 
compared with those without BRCA mutations. In 2016, another study revealed 347 
that a VEGF-dependent gene signature (VDGs) was overexpressed in OC 348 
BRCA mutation carriers [37]. An interesting hypothesis explaining the linking 349 
between BRCA1 mutation and VEGF overexpression in HGSOC has been 350 
recently proposed: in 2015 Desai A and Colleagues [38] pointed out that wild-351 
type BRCA1 binds to Ubc9, which induces Caveolin-1 expression, down-352 
regulates VEGF and regulates endothelial function in normal ovaries and 353 
fallopian tubes. In HGSOC with BRCA1 dysfunction, Ubc9 is not binded and 354 
this inhibits Caveolin-1 expression causing increased VEGF levels, loss of 355 
endothelial function and accumulation of ascites. Compared to these previous 356 
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studies, we also confirmed in our cohort the positive influence of BRCA 357 
mutations on OC patients’ survival [39,40], as well as the significant association 358 
between BRCA mutation and VEGF positivity determined VEGF positivity a 359 
good prognostic factor in our HGSOC series. This result may also reflect the 360 
highly selection of the sample analyzed, which only included HGSOC patients, 361 
who can also undergo secondary cytoreductive surgery for recurrence. These 362 
patients have usually good performance status and low tumor burden, so there 363 
is a selection of patients with a better clinical outcome[41]. Furthermore, 364 
patients have been treated in high volume centers, with high experience in 365 
surgical treatment of ovarian cancer. Most Centers have been also approved 366 
and allowed to participate in the LION (ClinicalTrials.gov Identifier: 367 
NCT00712218), DESKTOP III (ClinicalTrials.gov Identifier: NCT01166737) and 368 
TRUST (ClinicalTrials.gov Identifier: NCT02828618) studies, based on the high 369 
quality of the tumor debulking.  370 
Nevertheless, further studies aiming to assess the association between BRCA 371 
mutation and VEGF overexpression would provide new instrument to 372 
personalize treatment with anti-angiogenetic agents among BRCA-mutated 373 
and BRCA wild-type OC patients [42]. In this scenario, the randomized phase 374 
III clinical trial ENGOT-ov25/PAOLA-1 (ClinicalTrials.gov Identifier: 375 
NCT02477644), which combines in advanced OC patients bevacizumab-based 376 
first-line treatment with or without the PARP-Inhibitor olaparib, could be able to 377 
add evidence concerning functional impact of VEGF expression in tumors with 378 
impaired homologous DNA repair mechanism.  379 
To our knowledge, this is the first study analyzing the changes occurring in 380 
intratumoral vasculature during disease progression in the largest cohort of 381 
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paired primary and recurrent HGSOC samples. It firstly demonstrated that the 382 
vascular architecture within the tumor mass, in absence of anti-angiogenic 383 
agents administration, is maintained relatively stable during the natural course 384 
of the disease. Furthermore, the subanalysis on patients with known somatic 385 
BRCA status increases the value of findings by taking into account the impact 386 
of BRCA status on patients’ survival[39,40] and provides preliminary evidence 387 
of the correlation between VEGF-positivity and BRCA mutation. 388 
The main limitation of the study is its retrospective nature. One of the strengths 389 
of this analysis is the large sample size of paired primary and recurrent tumor 390 
tissue samples belonging to the same cancer subtype (n=222), the high quality 391 
of specimens and the systematization of multicentric patients’ clinico-392 
pathological data. Furthermore, inclusion of patients not subjected to the 393 
bevacizumab-based first-line chemotherapy, increase the reliability of the 394 
results in comparing intratumoral vasculature profiles from primary to recurrent 395 
disease.  396 
Future study on a larger population with known BRCA status, who has been 397 
subjected to bevacizumab-based first-line chemotherapy, is warranted to clarify 398 
the role of MVD and VEGF in predicting bevacizumab response in both BRCA-399 
wt and BRCA-mutated HGSOC patients.  400 
 401 
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LEGEND TO FIGURES AND TABLES  642 
 643 
Figure 1. CD31 immunohistochemistry staining for intratumoral MVD 644 
assessment: MVDhigh (a) and MVDlow (b) pOC samples; MVDhigh (c) and MVDlow 645 
(d) rOC samples. 400x magnification; MVD count among primary and recurrent 646 
tumours (box plot – e – and scatter plot – f). 647 
 648 
Figure 2. VEGF-A immunohistochemistry staining. VEGF-A IRS distribution in 649 
primary (a) and recurrent (d) tumor samples. pOCs, VEGF(+) (b) and VEGF(-) 650 
(c); rOCs, VEGF(+)  (e) and VEGF(-) (f); VEGF-A IRS among primary and 651 
recurrent tumours (box plot – g – and scatter plot – h). 652 
Figure 3. MVD and/or VEGF status and progression free survival after primary 653 
(PFI, a,b,c) and recurrent (PFS, d,e,f) disease. g-i: MVD and/or VEGF status at 654 
primary disease and overall survival. “x-axis”: months; “y-axis”: survival 655 
probability. 656 
 657 
Figure S1 (supplementary): MVDhigh and VEGF(+) co-staining frequency 658 
among pOCs versus rOCs (bar plot). Asterisk indicates significance (p=0.02) 659 
between pOCs and rOCs. 660 
 661 
Figure S2 (supplementary): CD3, CD4, CD8 and FoxP3 staining of 662 
intratumoral T lymphocytes. 663 
 664 
Figure S3 (supplementary): VEGF-A IRS changes from pOCs to rOCs among 665 
BRCA-wt (a - box plot – and c – scatter plot; Wilcoxon test: p=0.126; Spearman 666 
correlation test: p=0.290; Spearman coefficient -0.200) versus BRCA-mut 667 
patients (b – box plot – and d – scatter plot; Wilcoxon test: p=0.053; Spearman 668 
correlation test: p=0.226; Spearman coefficient 0.276). 669 
 670 
Table 1. Patients’ characteristics 671 
 672 
Table 2. Association of MVD and/or VEGF expression with patients’ 673 
clinicopathological characteristics (pOCs). 674 
 675 
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 676 
Table 3. multivariate analysis for OS carried out on a) the whole patients’ 677 
population (n=111), b) only somatic BRCA-tested population (n=52) and 678 
multivariate analysis for PFI carried out on c) the whole patients’ population 679 
(n=111), d) only somatic BRCA-tested population (n=52).  680 
 681 
Table S1 (supplementary): Overall survival (OS) by CD31 MVD quartile. 682 
 683 
Table S2 (Supplementary): Correlation between MVD and/or VEGF 684 
expression profile in pOC and Tumor Infiltrating Lymphocyte (TILs) phenotype. 685 
 686 
 687 
